MXPA05012596A - Inhibidores de quinasa, de indazol, bencisoxazol y bencisotiazol. - Google Patents

Inhibidores de quinasa, de indazol, bencisoxazol y bencisotiazol.

Info

Publication number
MXPA05012596A
MXPA05012596A MXPA05012596A MXPA05012596A MXPA05012596A MX PA05012596 A MXPA05012596 A MX PA05012596A MX PA05012596 A MXPA05012596 A MX PA05012596A MX PA05012596 A MXPA05012596 A MX PA05012596A MX PA05012596 A MXPA05012596 A MX PA05012596A
Authority
MX
Mexico
Prior art keywords
benzisoxazole
indazole
kinase inhibitors
compounds
benzisothiazole
Prior art date
Application number
MXPA05012596A
Other languages
English (en)
Inventor
Michael R Michaelides
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/443,254 external-priority patent/US20040235892A1/en
Priority claimed from US10/842,292 external-priority patent/US7297709B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MXPA05012596A publication Critical patent/MXPA05012596A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

Los compuestos que tienen la formula (I) son utiles para inhibir las tirosina-quinasas de proteina. La presente invencion describe tambien metodos para formar los compuestos; composiciones que contienen los compuestos, y metodos de tratamiento que usan los compuestos.
MXPA05012596A 2003-05-22 2004-05-21 Inhibidores de quinasa, de indazol, bencisoxazol y bencisotiazol. MXPA05012596A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/443,254 US20040235892A1 (en) 2003-05-22 2003-05-22 Indazole and benzisoxazole kinase inhibitors
US10/842,292 US7297709B2 (en) 2003-05-22 2004-05-10 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
PCT/US2004/016166 WO2004113304A1 (en) 2003-05-22 2004-05-21 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA05012596A true MXPA05012596A (es) 2006-02-22

Family

ID=33544008

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012596A MXPA05012596A (es) 2003-05-22 2004-05-21 Inhibidores de quinasa, de indazol, bencisoxazol y bencisotiazol.

Country Status (21)

Country Link
EP (2) EP1638941B1 (es)
JP (2) JP4810427B2 (es)
KR (1) KR100976076B1 (es)
CN (2) CN102417487A (es)
AT (1) ATE469888T1 (es)
AU (2) AU2004249675B2 (es)
BR (1) BRPI0410745A (es)
CA (1) CA2526430C (es)
CY (1) CY1110742T1 (es)
DE (1) DE602004027490D1 (es)
DK (1) DK1638941T3 (es)
ES (2) ES2398074T3 (es)
HK (2) HK1089172A1 (es)
IL (1) IL171976A0 (es)
MX (1) MXPA05012596A (es)
NZ (1) NZ543614A (es)
PL (1) PL1638941T3 (es)
PT (1) PT1638941E (es)
SI (1) SI1638941T1 (es)
TW (1) TWI328579B (es)
WO (1) WO2004113304A1 (es)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2733577T3 (es) 2003-08-06 2019-12-02 Senomyx Inc Nuevos aromas, modificadores del aroma, saborizantes, intensificadores del sabor, saborizantes umami o dulces y/o intensificadores y uso de los mismos
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102004028862A1 (de) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
MX2007005120A (es) * 2004-10-29 2007-07-16 Abbott Lab Nuevos inhibidores de cinasa.
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
US7842809B2 (en) 2005-01-24 2010-11-30 Bayer Schering Pharma Ag Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
EP1683796A1 (en) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
RU2404776C2 (ru) * 2005-01-28 2010-11-27 Новартис Аг ПРИМЕНЕНИЕ ПИРИМИДИЛАМИНОБЕНЗАМИДОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ЧУВСТВИТЕЛЬНЫХ К МОДУЛЯЦИИ АКТИВНОСТИ КИНАЗЫ Тie-2
BRPI0607006B1 (pt) 2005-02-04 2017-05-16 Senomyx Inc compostos que compreendem funções orgânicas de hetero arilas ligadas e seus usos como novos modificadores, flavorizantes e promotores do sabor umami para composições comestíveis
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
CN101346128B (zh) * 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CN102775350A (zh) * 2006-04-14 2012-11-14 雅培制药有限公司 制备抑制香草素亚型1（vr1）受体的吲唑基脲的方法
CN105152940A (zh) 2006-04-21 2015-12-16 西诺米克斯公司 含有高效鲜味调料的可食用组合物及其制备方法
EP1870410A1 (en) 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1867648A1 (en) * 2006-06-13 2007-12-19 Bayer Schering Pharma Aktiengesellschaft Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them.
EP1867647A1 (en) * 2006-06-13 2007-12-19 Bayer Schering Pharma Aktiengesellschaft Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them.
TW200815438A (en) 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW200815437A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
TW200833690A (en) * 2006-12-15 2008-08-16 Bayer Schering Pharma Ag 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1932845A1 (en) * 2006-12-15 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
ES2457418T3 (es) * 2007-07-16 2014-04-25 Abbvie Inc. Indazoles, bencisoxazoles y bencisotiazoles como inhibidores de proteína cinasas
US7772404B2 (en) * 2007-10-19 2010-08-10 Abbott Laboratories Crystalline form 2 of the chemotherapeutic N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea
US7994208B2 (en) 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic
US7943782B2 (en) 2007-10-19 2011-05-17 Abbott Laboratories Crystalline chemotherapeutic
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic
US7960564B2 (en) 2007-10-19 2011-06-14 Abbott Laboratories Crystalline chemotherapeutic
ES2554812T3 (es) 2007-11-09 2015-12-23 Genentech, Inc. Composiciones de antagonistas de quinasa 1 de tipo receptor de activina y métodos de uso
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
JP5913980B2 (ja) 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド 免疫グロブリン変異体及びその用途
ES2548141T3 (es) * 2008-11-20 2015-10-14 Glaxosmithkline Llc Compuestos químicos
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
MX2011006875A (es) 2008-12-23 2011-07-20 Genentech Inc Metodos y composiciones para uso en diagnostico de pacientes con cancer.
WO2010101989A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
AU2010221438C1 (en) * 2009-03-03 2015-01-29 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
KR20160135372A (ko) * 2009-03-03 2016-11-25 알콘 리서치, 리미티드 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
MX2011010012A (es) 2009-03-25 2011-12-06 Genentech Inc NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9073939B2 (en) * 2009-07-10 2015-07-07 Bayer Intellectual Property Gmbh Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof
CN102482715A (zh) 2009-07-13 2012-05-30 霍夫曼-拉罗奇有限公司 用于癌症治疗的诊断方法和组合物
MX2012001974A (es) * 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.
CN102216300B (zh) * 2009-09-30 2014-10-22 贝达药业股份有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
TWI505836B (zh) 2009-12-11 2015-11-01 Genentech Inc 抗－ｖｅｇｆ－ｃ抗體及其使用方法
SG2014011340A (en) 2009-12-21 2014-07-30 Genentech Inc Antibody formulation
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011115725A2 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
EP2640377B1 (en) 2010-11-15 2018-12-26 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
CN108178789B (zh) 2011-04-20 2021-11-02 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
US20140107151A1 (en) 2011-05-17 2014-04-17 Principia Biophama Inc. Tyrosine kinase inhibitors
CN102432595B (zh) * 2011-09-14 2013-09-25 湖南有色凯铂生物药业有限公司 N-吲哚-1-酰胺类化合物及作为抗癌药物的应用
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
CA2900680C (en) 2013-02-20 2021-08-10 Kala Pharmaceuticals, Inc. Quinoline and quinazoline compounds and uses thereof for treating and/or preventing diseases
RU2019120404A (ru) 2013-03-13 2019-08-06 Дженентек, Инк. Составы антител
AU2014259956A1 (en) 2013-05-01 2015-11-12 Five Prime Therapeutics, Inc. Methods of treating cancer
WO2014190147A2 (en) 2013-05-23 2014-11-27 Five Prime Therapeutics, Inc. Methods of treating cancer
JP6469661B2 (ja) 2013-06-11 2019-02-13 カラ ファーマシューティカルズ インコーポレイテッド 尿素誘導体及びその使用
US8759538B1 (en) 2013-06-13 2014-06-24 Abbvie Inc. Crystalline chemotherapeutic
CN103524421B (zh) * 2013-09-29 2015-04-01 镇江蓝德特药业科技有限公司 新型萘脲类衍生物及其医疗应用
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
EA035481B1 (ru) 2013-10-25 2020-06-23 Акселерон Фарма, Инк. Эндоглиновые пептиды для лечения фиброзных заболеваний
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
EP2985043A1 (en) 2014-08-14 2016-02-17 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Process for manufacturing a customizable medical device and device obtained by said process
MX2017003121A (es) 2014-09-15 2017-08-02 Genentech Inc Formulaciones de anticuerpos.
CN104326985A (zh) * 2014-09-24 2015-02-04 安润医药科技（苏州）有限公司 利你法尼的制备方法
TWI711463B (zh) 2014-10-29 2020-12-01 美商戊瑞治療有限公司 用於癌症之組合療法
EP3230272B1 (en) 2014-12-10 2020-08-19 Kala Pharmaceuticals, Inc. 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN104725319A (zh) * 2015-03-11 2015-06-24 西安交通大学 一种具有抗肿瘤活性的1h-吲唑-3-氨基联苯脲类化合物及其制备方法和应用
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
PT3283527T (pt) 2015-04-13 2021-03-03 Five Prime Therapeutics Inc Terapêutica de combinação para o cancro
WO2016187220A2 (en) 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3325512B1 (en) 2015-07-23 2023-09-06 Inhibrx, Inc. Multivalent and multispecific gitr-binding fusion proteins
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
BR112018008865A8 (pt) 2015-11-02 2019-02-26 Five Prime Therapeutics Inc polipeptídeos do domínio extracelular cd80 e seu uso no tratamento do câncer
WO2017091580A1 (en) 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
ES2904615T3 (es) * 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
CN105906568A (zh) * 2016-04-28 2016-08-31 西安交通大学 一种具有抗肿瘤活性的环丙二酰胺化合物及其制备方法和应用
US20190263919A1 (en) 2016-07-01 2019-08-29 Five Prime Therapeutics, Inc. Combined anti tumor therapy with a gitr agonist and cpg
EP3543228B1 (en) * 2016-11-17 2022-12-28 3D Medicines (Beijing) Co., Ltd. Compound having anticancer activity, and preparation method and application thereof
CN108117551B (zh) * 2016-11-29 2020-03-27 华东理工大学 取代(1H-吡唑[3,4-b]吡啶)脲类化合物及其抗肿瘤用途
EP3601353A1 (en) 2017-03-31 2020-02-05 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
MX2019012849A (es) 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
EA038912B1 (ru) 2017-08-01 2021-11-09 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
KR20200051024A (ko) 2017-09-13 2020-05-12 파이브 프라임 테라퓨틱스, 인크. 췌장암에 대한 조합 항-csf1r 및 항-pd-1 항체 조합 요법
US20210017283A1 (en) 2018-03-21 2021-01-21 Five Prime Therapeutics, Inc. Antibodies Binding to Vista at Acidic pH
TWI819024B (zh) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 結合至ｉｌｔ４的抗體
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
US20210340214A1 (en) 2018-08-29 2021-11-04 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
CA3125039A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
WO2020172482A2 (en) 2019-02-22 2020-08-27 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors
KR20220065816A (ko) 2019-09-19 2022-05-20 브리스톨-마이어스 스큅 컴퍼니 산성 pH에서 VISTA에 결합하는 항체
WO2021092084A1 (en) 2019-11-04 2021-05-14 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
JP2023517794A (ja) 2020-01-06 2023-04-27 ハイファイバイオ（ホンコン）リミテッド 抗ｔｎｆｒ２抗体及びその使用
JP2023510429A (ja) 2020-01-07 2023-03-13 ハイファイバイオ （エイチケー） リミテッド 抗ガレクチン－９抗体およびその使用
WO2021173903A1 (en) 2020-02-26 2021-09-02 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein therapy
EP4192866A2 (en) 2020-08-10 2023-06-14 GV20 Therapeutics LLC Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
EP4228764A1 (en) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2023003995A1 (en) 2021-07-23 2023-01-26 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2024015993A1 (en) 2022-07-15 2024-01-18 Fibrogen, Inc. Modified anti-galectin-9 antibody and uses thereof
WO2024020579A1 (en) 2022-07-22 2024-01-25 Bristol-Myers Squibb Company Antibodies binding to human pad4 and uses thereof
WO2024040216A2 (en) 2022-08-19 2024-02-22 Fibrogen, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2971842A (en) * 1956-03-21 1961-02-14 Gen Aniline & Film Corp Light sensitive layers for photomechanical reproduction
GB816283A (en) * 1957-06-28 1959-07-08 Corson G & W H Road building
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AU1818400A (en) * 1998-11-12 2000-05-29 Eli Lilly And Company Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
JP2004518669A (ja) * 2000-12-20 2004-06-24 スージェン・インコーポレーテッド ４−アリール置換インドリノン
AU2002353186A1 (en) * 2001-12-19 2003-06-30 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
AU2003221184A1 (en) * 2002-03-29 2003-10-27 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for endothelial disorder
EP1506176B1 (en) * 2002-05-17 2013-04-24 Pfizer Italia S.r.l. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
WO2004022544A1 (fr) * 2002-09-05 2004-03-18 Aventis Pharma S.A. Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
MXPA05005554A (es) * 2002-12-12 2005-07-26 Aventis Pharma Sa Derivados de aminoindazol y su utilizacion como inhibidores de quinasas.

Also Published As

Publication number Publication date
ATE469888T1 (de) 2010-06-15
TW200504015A (en) 2005-02-01
ES2346538T3 (es) 2010-10-18
CN1826324B (zh) 2011-12-07
KR20060023970A (ko) 2006-03-15
CN1826324A (zh) 2006-08-30
AU2004249675A1 (en) 2004-12-29
NZ543614A (en) 2009-09-25
TWI328579B (en) 2010-08-11
DK1638941T3 (da) 2010-10-11
JP2007500226A (ja) 2007-01-11
EP2246333B1 (en) 2012-10-24
CA2526430A1 (en) 2004-12-29
HK1149757A1 (en) 2011-10-14
JP2011088918A (ja) 2011-05-06
DE602004027490D1 (de) 2010-07-15
ES2398074T3 (es) 2013-03-13
PL1638941T3 (pl) 2010-11-30
SI1638941T1 (sl) 2010-11-30
WO2004113304A1 (en) 2004-12-29
EP1638941B1 (en) 2010-06-02
KR100976076B1 (ko) 2010-08-17
CA2526430C (en) 2012-07-10
BRPI0410745A (pt) 2006-06-27
EP1638941A1 (en) 2006-03-29
EP2246333A1 (en) 2010-11-03
CN102417487A (zh) 2012-04-18
IL171976A0 (en) 2006-04-10
PT1638941E (pt) 2010-08-24
JP5336461B2 (ja) 2013-11-06
AU2004249675B2 (en) 2010-04-15
HK1089172A1 (en) 2006-11-24
CY1110742T1 (el) 2015-06-10
AU2010202984A1 (en) 2010-08-05
JP4810427B2 (ja) 2011-11-09

Similar Documents

Publication Publication Date Title
MXPA05012596A (es) Inhibidores de quinasa, de indazol, bencisoxazol y bencisotiazol.
WO2006050109A3 (en) Novel kinase inhibitors
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
MXPA06010904A (es) Inhibidores de pirazol cinasa triciclicos.
WO2007079164A3 (en) Protein kinase inhibitors
HK1087700A1 (en) Triazolopyridazines as protein kinases inhibitors
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
YU84603A (sh) Novi inhibitori tirozin kinaze
HK1065033A1 (en) Thiazole compounds useful as inhibitors or proteinkinases
AU2003297160A1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
ZA200702645B (en) Diaminotriazole compounds useful as protein kinase inhibitors
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
WO2004072029A3 (en) Pyrazolopyridazines useful as inhibitors of protein kinases
MXPA04005809A (es) Inhibidores de proteinas quinasas.
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general
GB Transfer or rights